391 related articles for article (PubMed ID: 28536305)
1. Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus.
Eriksson E; Milenova I; Wenthe J; Ståhle M; Leja-Jarblad J; Ullenhag G; Dimberg A; Moreno R; Alemany R; Loskog A
Clin Cancer Res; 2017 Oct; 23(19):5846-5857. PubMed ID: 28536305
[No Abstract] [Full Text] [Related]
2. Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy.
Wenthe J; Naseri S; Labani-Motlagh A; Enblad G; Wikström KI; Eriksson E; Loskog A; Lövgren T
Cancer Immunol Immunother; 2021 Oct; 70(10):2851-2865. PubMed ID: 33666760
[TBL] [Abstract][Full Text] [Related]
3. Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment.
Eriksson E; Moreno R; Milenova I; Liljenfeldt L; Dieterich LC; Christiansson L; Karlsson H; Ullenhag G; Mangsbo SM; Dimberg A; Alemany R; Loskog A
Gene Ther; 2017 Feb; 24(2):92-103. PubMed ID: 27906162
[TBL] [Abstract][Full Text] [Related]
4. IL-6 Signaling Blockade during CD40-Mediated Immune Activation Favors Antitumor Factors by Reducing TGF-β, Collagen Type I, and PD-L1/PD-1.
Eriksson E; Milenova I; Wenthe J; Moreno R; Alemany R; Loskog A
J Immunol; 2019 Feb; 202(3):787-798. PubMed ID: 30617223
[TBL] [Abstract][Full Text] [Related]
5. Human dendritic cells efficiently phagocytose adenoviral oncolysate but require additional stimulation to mature.
Schierer S; Hesse A; Knippertz I; Kaempgen E; Baur AS; Schuler G; Steinkasserer A; Nettelbeck DM
Int J Cancer; 2012 Apr; 130(7):1682-94. PubMed ID: 21557217
[TBL] [Abstract][Full Text] [Related]
6. Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40.
Wenthe J; Naseri S; Hellström AC; Wiklund HJ; Eriksson E; Loskog A
Cancer Gene Ther; 2020 Dec; 27(12):948-959. PubMed ID: 32355275
[TBL] [Abstract][Full Text] [Related]
7. Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model.
Na Y; Choi JW; Kasala D; Hong J; Oh E; Li Y; Jung SJ; Kim SW; Yun CO
J Control Release; 2015 Dec; 220(Pt B):766-82. PubMed ID: 26471393
[TBL] [Abstract][Full Text] [Related]
8. An oncolytic vaccinia virus armed with anti-human-PD-1 antibody and anti-human-4-1BB antibody double genes for cancer-targeted therapy.
Shi Z; Liu B; Huang C; Xie W; Cen Y; Chen L; Liang M
Biochem Biophys Res Commun; 2021 Jun; 559():176-182. PubMed ID: 33945995
[TBL] [Abstract][Full Text] [Related]
9. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus.
Diaconu I; Cerullo V; Hirvinen ML; Escutenaire S; Ugolini M; Pesonen SK; Bramante S; Parviainen S; Kanerva A; Loskog AS; Eliopoulos AG; Pesonen S; Hemminki A
Cancer Res; 2012 May; 72(9):2327-38. PubMed ID: 22396493
[TBL] [Abstract][Full Text] [Related]
10. Growth inhibition of human multiple myeloma cells by an oncolytic adenovirus carrying the CD40 ligand transgene.
Fernandes MS; Gomes EM; Butcher LD; Hernandez-Alcoceba R; Chang D; Kansopon J; Newman J; Stone MJ; Tong AW
Clin Cancer Res; 2009 Aug; 15(15):4847-56. PubMed ID: 19622582
[TBL] [Abstract][Full Text] [Related]
11. Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models.
Wenthe J; Eriksson E; Hellström AC; Moreno R; Ullenhag G; Alemany R; Lövgren T; Loskog A
J Transl Med; 2023 Jul; 21(1):506. PubMed ID: 37501121
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer.
Liikanen I; Tähtinen S; Guse K; Gutmann T; Savola P; Oksanen M; Kanerva A; Hemminki A
Mol Cancer Ther; 2016 Sep; 15(9):2259-69. PubMed ID: 27458139
[TBL] [Abstract][Full Text] [Related]
13. Newcastle disease virus mediates pancreatic tumor rejection via NK cell activation and prevents cancer relapse by prompting adaptive immunity.
Schwaiger T; Knittler MR; Grund C; Roemer-Oberdoerfer A; Kapp JF; Lerch MM; Mettenleiter TC; Mayerle J; Blohm U
Int J Cancer; 2017 Dec; 141(12):2505-2516. PubMed ID: 28857157
[TBL] [Abstract][Full Text] [Related]
14. The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model.
Li X; Wang P; Li H; Du X; Liu M; Huang Q; Wang Y; Wang S
Clin Cancer Res; 2017 Jan; 23(1):239-249. PubMed ID: 27435398
[TBL] [Abstract][Full Text] [Related]
15. CD40 ligand and tdTomato-armed vaccinia virus for induction of antitumor immune response and tumor imaging.
Parviainen S; Ahonen M; Diaconu I; Hirvinen M; Karttunen Å; Vähä-Koskela M; Hemminki A; Cerullo V
Gene Ther; 2014 Feb; 21(2):195-204. PubMed ID: 24305418
[TBL] [Abstract][Full Text] [Related]
16. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
Watanabe K; Luo Y; Da T; Guedan S; Ruella M; Scholler J; Keith B; Young RM; Engels B; Sorsa S; Siurala M; Havunen R; Tähtinen S; Hemminki A; June CH
JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618658
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy.
Fajardo CA; Guedan S; Rojas LA; Moreno R; Arias-Badia M; de Sostoa J; June CH; Alemany R
Cancer Res; 2017 Apr; 77(8):2052-2063. PubMed ID: 28143835
[TBL] [Abstract][Full Text] [Related]
19. Systemic immunity upon local oncolytic virotherapy armed with immunostimulatory genes may be supported by tumor-derived exosomes.
Labani-Motlagh A; Naseri S; Wenthe J; Eriksson E; Loskog A
Mol Ther Oncolytics; 2021 Mar; 20():508-518. PubMed ID: 33738337
[TBL] [Abstract][Full Text] [Related]
20. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.
Srivastava RM; Trivedi S; Concha-Benavente F; Gibson SP; Reeder C; Ferrone S; Ferris RL
Clin Cancer Res; 2017 Feb; 23(3):707-716. PubMed ID: 27496866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
